Hot Features
프리미엄
실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being de... Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease. 더 보기
- Reported positive topline phase 3 data for veligrotug from THRIVE in patients with active thyroid eye disease (TED); on track to report topline data from THRIVE-2 in chronic patients in...
Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare...
| 기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.82 | 9.05923344948 | 20.09 | 22.2298 | 19.46 | 1082973 | 20.48765164 | CS |
| 4 | -0.79 | -3.48017621145 | 22.7 | 27.2 | 19.46 | 1229602 | 22.03336846 | CS |
| 12 | 7.55 | 52.5766016713 | 14.36 | 27.2 | 13.2 | 1559495 | 21.03657098 | CS |
| 26 | 9.61 | 78.1300813008 | 12.3 | 27.2 | 11.4 | 1256398 | 18.099071 | CS |
| 52 | 6.12 | 38.7587080431 | 15.79 | 27.2 | 11.4 | 1097620 | 18.0438279 | CS |
| 156 | 3.83 | 21.1836283186 | 18.08 | 39 | 9.47 | 719438 | 19.83094044 | CS |
| 260 | 0.52 | 2.43104254324 | 21.39 | 39 | 9.47 | 580273 | 19.64762448 | CS |
Monksdream
2 월 전
it_happens
3 월 전
power11
3 월 전
it_happens
3 월 전
power11
3 월 전
it_happens
3 월 전
Monksdream
3 월 전
Apprentice
3 년 전
Apprentice
3 년 전
crudeoil24
3 년 전
